Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2000 Aug;2(4):433-40.

Developments in suicide genes for preclinical and clinical applications.

Author information

  • 1Baylor College of Medicine, Department of Immunology, One Baylor Plaza/M929, Houston, TX 77030, USA. dspencer@bcm.tmc.edu

Abstract

The graduation of gene therapy from unfulfilled dreams to conventional therapy for genetic and acquired disorders will require a mastery of multiple disparate components including gene delivery vectors, regulated tissue-specific gene expression, control of immunity and manipulation of cell viability. Improvements in suicide genes have opened up a whole new treatment modality for treating hyperproliferative disorders and for designing animal models for disease. Along with herpes simplex virus-1 thymidine kinase, a host of additional suicide genes have been developed. A critical comparison of these will follow along with progress in utilizing these reagents for therapeutic benefits.

PMID:
11249774
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk